Stock Titan Trading tools for traders and investors.

-

02:30:23 AM

Last EIGR Stock Market News

EIGR - Eiger BioPharmaceuticals Inc

02/23/21 8:00 AM

Nasdaq : EIGR

Eiger Announces Publication of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia in Journal of Clinical Endocrinology & Metabolism

Eiger BioPharmaceuticals, Inc (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced that positive results

RHEA-AI

neutral

02/08/21 8:00 AM

Nasdaq : EIGR

Eiger Announces ILIAD Study Results of Peginterferon Lambda in COVID-19 Published in Lancet Respiratory Medicine 2021

Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced that final results from the

RHEA-AI

neutral

01/25/21 8:00 AM

Nasdaq : EIGR

Eiger BioPharmaceuticals Announces U.S. Commercial Availability of Zokinvy(TM) (lonafarnib), the First and Only Treatment Approved for Progeria and Processing-Deficient Progeroid Laminopathies

Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today announced the commercial launch and

RHEA-AI

neutral

01/07/21 8:00 AM

Nasdaq : EIGR

Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans

Eiger BioPharmaceuticals, Inc (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development and commercialization of foundational therapies for Hepatitis Delta Virus (HDV) infection, today updated on progress across its

RHEA-AI

very positive

11/25/20 8:42 AM

Nasdaq : EIGR

Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Zokinvy (TM)

RHEA-AI

positive

11/23/20 8:00 AM

Nasdaq : EIGR

Eiger BioPharmaceuticals Sells Priority Review Voucher for $95 Million

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that it has entered into a definitive agreement to sell its Priority Review

RHEA-AI

very positive

11/20/20 5:53 PM

Nasdaq : EIGR

Eiger BioPharmaceuticals Announces FDA Approval of Zokinvy(TM) (lonafarnib): The First Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Zokinvy TM

RHEA-AI

positive

11/17/20 8:00 AM

Nasdaq : EIGR

Eiger Announces Positive Peginterferon Lambda - Lonafarnib Combination End of Study Results from Phase 2 LIFT HDV Study in Late-Breaker Session at The Liver Meeting Digital Experience(TM) 2020

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of first-in-class therapies for serious rare and ultra-rare diseases, today announced a late-breaker oral presentation of Phase 2 LIFT ( L ambda I nter F

RHEA-AI

neutral

11/16/20 4:05 PM

Nasdaq : EIGR

Eiger Announces Case Studies Demonstrating Regression of Liver Fibrosis Following 48 Weeks of Therapy with Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection Presented at The Liver Meeting Digital Experience(TM) 2020

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of first-in-class therapies for serious rare and ultra-rare diseases, today announced a poster presentation of two case studies from the completed Phase 2

RHEA-AI

neutral

11/11/20 8:00 AM

Nasdaq : EIGR

Eiger Bio to Participate in November 2020 Investor Conferences

Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, today announced that management will participate in two investor conferences in

RHEA-AI

neutral